Interim analysis of the 2nd chance protocol: A multicenter trial of daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplantation Meeting Abstract
| Authors: | Shah, G. L.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R. L.; Costa, L. J.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; Shulman, L.; Obadi, O.; Acosta, J.; Hassoun, H.; Hultcrantz, M.; Korde, N. S.; Mailankody, S.; Tan, C. R.; Shah, U. A.; Lesokhin, A. M.; Lahoud, O. B.; Scordo, M.; Chung, D. J.; Landau, H. J.; Giralt, S. A. |
| Abstract Title: | Interim analysis of the 2nd chance protocol: A multicenter trial of daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplantation |
| Meeting Title: | 2022 Tandem Meetings of ASTCT and CIBMTR |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 28 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2022 Apr 23-26 |
| Meeting Location: | Salt Lake City, UT |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-03-01 |
| Start Page: | S415 |
| End Page: | S416 |
| Language: | English |
| DOI: | 10.1016/S2666-6367(22)00693-5 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: 534 -- Located within the section named "Poster Session - Lymphoma/Myeloma - Clinical" |
Altmetric
Citation Impact
BMJ Impact Analytics
